Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 4 of 30
Addictive Threshold of Nicotine
NCT06096714
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
SGM Evidenced-Based Mental Healthcare Implementation
NCT05890404
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
NCT05207085
Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1
NCT06069791
Evaluating the Unmet Needs of Older Adults to Promote Functional Recovery After a Critical Illness
NCT06006000
Intradermal Influenza Vaccination
NCT06067555
The OBSERVE Protocol
NCT06725277
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
NCT06074068
Pregnenolone for the Treatment of Alcohol Use Disorder
NCT05781009
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
NCT04974671
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
NCT06100705
AMPK-activation by Metformin in FSGS: AMP-FSGS
NCT06090227
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
NCT06105931
Supporting Parents in Affirming Their Children's Experiences of Stigma
NCT05919849
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
NCT05957159
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
NCT06004830
Systems Investigation of Vaccine Responses in Aging and Frailty
NCT05291676
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
NCT05906511
Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy
NCT05730309
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
NCT06042517
Empagliflozin in Patients With Cirrhosis and Ascites
NCT05726032
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
NCT05737693
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
NCT05753059
Expanding Medication-Assisted Therapies in Central Asia
NCT05579470
Effects of Acute and Chronic Empagliflozin Heart Failure
NCT05553938
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
NCT05547048
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
NCT05067621
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
NCT05313243
Stepped Care for Patients to Optimize Whole Recovery
NCT05155163
Acute Effects of Focused Ultrasound Modulation on EEG Behavior in Status Epilepticus Patients
NCT05784805
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
NCT05884190
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
NCT05838521
An Evaluation of Hip Preservation Outcomes
NCT05746533
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
NCT05586581
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
NCT05786417
Social Disconnection Study
NCT06705348
SHAPE Test for Preoperative Risk Stratification
NCT05743673
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
NCT05761561
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
NCT05786066
OMAR Opioid Use Disorder
NCT05683184
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT05671991
Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction
NCT05012982
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2
NCT05736549
Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health
NCT05509166
TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven
NCT05723614
Neuroplasticity in Maternal Opioid Use Disorder (OUD)
NCT05495984
Ultrasound Effects on Glycemic Control in T2DM
NCT05354947
Neurofeedback From the Supplementary Motor Area for Tourette Syndrome
NCT05558566
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.